Suitable for use in IFA, ELISA and immunoblotting. A starting range of 1: 10-1: 50 is suggested for IFA and blotting and 1: 20-1: 200 for ELISA. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.1 mg/mL (OD280 nm, E0.1% = 1.4)
Buffer
0.01 M PBS, pH 7.2 containing 0.09 % sodium azide as preservative and no stabilizers.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
Toxoplasma Gondii P30
Hintergrund
Toxoplasma is a crescent shaped sporozoan that lives as an intracellular parasite in various tissues of many vertebrates and completes its life cycle in a single host. Its life cycle includes two phases called the intestinal (or enteroepithelial) and extraintestinal phases. The intestinal phase produces oocysts and occurs only in cats, wild as well as domesticated. The extraintestinal phase occurs in all infected animals including cats, and produces tachyzoites (actively proliferating trophozoites) and eventually, bradyzoites (slowly growing trophozoites) or zoitocysts. Infection due to Toxoplasma gondii occurs in pregnant women where a variable degree of immunosuppression may exist or in patients receiving immunosuppressive drug therapy. Toxoplasma infects tissue of the GI tract where an active infection is accompanied by fever and enlargement of the spleen. Symptoms of toxoplasmosis are generally mild but severe infection of lymph nodes may occur. Congenital toxoplasmosis, in which the maternal infection is transmitted during pregnancy, can produce blindness or mental retardation in the newborn.